Advanced Microbubbles is a technology company.
Advanced Microbubbles has raised $250K across 1 funding round.
Advanced Microbubbles has raised $250K in total across 1 funding round.
Advanced Microbubbles, Inc. is a biotechnology company founded in 2020 and based in Newark, California, that develops and manufactures size-isolated, monodisperse, ultrasound-triggered microbubbles (SIMBs) for preclinical research in drug delivery and gene therapy.[1][2][3][4] The company serves biomedical and physical sciences researchers, addressing key challenges in anticancer drug delivery such as poor tumor penetration (less than 1% of injected drugs reach the target), off-target toxicity, and severe side effects like weight loss, hair loss, and vomiting.[1][4] Their SIMBs enable precise, low-dose delivery when triggered by focused ultrasound, with preclinical data showing control of high-risk neuroblastoma, blood-brain barrier opening, improved pancreatic cancer immunotherapy efficacy, and elimination of chemo-toxic side effects from liposomal doxorubicin.[1][4] Currently in early stages with revenue under $5 million and fewer than 25 employees, the company sells products to researchers now while pursuing a 505(b)(2) regulatory path to leverage FDA-approved chemotherapy safety data for faster market entry.[1][3]
Advanced Microbubbles was founded in 2020 by Jameel Feshitan, PhD (Co-Founder & CEO), Connor Slagle (Co-Founder & CTO), and Shashank Sirsi, PhD (Co-Founder & CSO), all with expertise in microbubble engineering and ultrasound applications.[1][2] The idea emerged from recognizing limitations in traditional drug delivery, particularly for hard-to-treat cancers where biological barriers like the tumor endothelium or blood-brain barrier block effective penetration.[1][4] Early traction came from developing the "holy grail" of uniform-sized, stable microbubbles that, when combined with focused ultrasound, enhance drug uptake into tumors at low doses, reducing side effects—a breakthrough validated in preclinical studies on neuroblastoma and other models.[1][4] Headquartered at 39655 Eureka Drive in Newark, California, the company quickly positioned itself to supply these custom microbubbles to researchers, transforming focused ultrasound research toward clinical applications.[1][2][3]
Advanced Microbubbles rides the wave of noninvasive, targeted therapies in oncology and neurology, where ultrasound-mediated drug delivery addresses failures of systemic chemotherapy amid rising demand for precision medicine.[1][4] Timing aligns with advances in focused ultrasound (e.g., FDA-approved for essential tremor and growing in oncology trials), enabling their SIMBs to enhance penetration through biological barriers—a critical need as cancer therapies shift toward combinations like immunotherapy and low-dose chemo.[1][4] Market forces favoring them include expanding preclinical research funding, biotech investor interest in drug delivery platforms, and regulatory tailwinds from 505(b)(2) pathways that shorten timelines versus full NDAs.[1] By supplying standardized microbubbles, they lower barriers for researchers, accelerating ecosystem-wide innovation in ultrasound-triggered treatments and influencing shifts from high-dose, toxic regimens to safer, efficacious alternatives.[2][3][4]
Next steps likely include scaling preclinical sales, advancing neuroblastoma or pancreatic cancer programs toward IND filings via 505(b)(2), and partnerships with ultrasound device firms or pharma for clinical trials.[1] Trends like AI-optimized ultrasound focusing, immunotherapy combos, and blood-brain barrier tech for brain cancers will propel their platform, potentially capturing a slice of the $10B+ oncology drug delivery market. Their influence could evolve from research enabler to clinical disruptor, humanizing biotech by slashing chemo side effects—echoing their origin in solving the "less than 1% penetration" crisis for transformative patient outcomes.[1][4]
Advanced Microbubbles has raised $250K in total across 1 funding round.
Advanced Microbubbles's investors include Mayfield, SOSV.
Advanced Microbubbles has raised $250K across 1 funding round. Most recently, it raised $250K Seed in May 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2020 | $250K Seed | Mayfield, SOSV |